1. Home
  2. SENEA vs TBPH Comparison

SENEA vs TBPH Comparison

Compare SENEA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seneca Foods Corp.

SENEA

Seneca Foods Corp.

HOLD

Current Price

$139.86

Market Cap

908.7M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.34

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENEA
TBPH
Founded
1949
2013
Country
United States
United States
Employees
6895
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
908.7M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SENEA
TBPH
Price
$139.86
$16.34
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$18.40
AVG Volume (30 Days)
77.2K
282.6K
Earning Date
06-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
N/A
N/A
P/E Ratio
$13.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.99
$9.10
52 Week High
$167.52
$21.03

Technical Indicators

Market Signals
Indicator
SENEA
TBPH
Relative Strength Index (RSI) 48.04 46.74
Support Level $138.19 $16.14
Resistance Level $148.36 $17.21
Average True Range (ATR) 5.66 0.38
MACD 0.39 -0.07
Stochastic Oscillator 43.78 29.31

Price Performance

Historical Comparison
SENEA
TBPH

About SENEA Seneca Foods Corp.

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: